Current/ Expected Orderbook/ Pending Orders?

The document does not explicitly mention the current or expected order book or pending orders in precise numbers. However, it is mentioned that there are secured annual contracts with some major customers, especially in products like DCB. The company is confident of recovering volumes in the second half of the year once customer inventory corrections stabilize. Export volumes, particularly for MMA, are strong, with 20,000-22,000 tons exported in July including deferred shipments. Expansion projects such as Zone-IV and Multipurpose Plant (MPP) are underway with phased commissioning planned from

Any current/future new fundraising through debt or equity?

The company has become more stringent in capital allocation over the past year. Current and upcoming capex projects like MMA expansions and Zone-IV are largely committed from earlier decisions, with a tapering overall capex trend. Capex guidance for FY26 is around Rs. 1,000 crore, down from approximately Rs. 1,300-1,400 crore the previous year. Future capex plans will be evaluated rigorously based on demand and return criteria. No explicit mention of fresh fundraising through debt or equity in the provided transcript. Focus appears to be on optimizing current assets, cost savings, and phased p

Any current/future capex/capital investment/strategic investment?

Ongoing capacity enhancements include scaling up Nitrotoluene capacity from 30 to 45 KTPA and Ethylation from 10 to 30 KTPA, currently in ramp-up phase. MMA capacity scaled up from 200 KTPA to 260 KTPA, with potential for further expansion with limited capex. Zone-IV project commissioning is expected in a phased manner from H2 FY26, introducing newer high-margin products in advanced polymers, agrochemicals, and pharmaceuticals. Augene Chemical Pvt Ltd (JV with UPL) progressing well, commissioning expected in H1 CY26, with market development underway. Re Aarti Pvt Ltd project through Aa

Future growth expectations in sales/revenue/volumes?

Growth levers are clear and being implemented to achieve Rs. 1,800 crore revenue target with 20-25% CAGR. Focus on expanding global markets, especially beyond the US for key products like MMA due to tariff uncertainties. Capacity expansions, such as scaling MMA capacity from 200 KTPA to 260 KTPA, are ongoing with minor additional CAPEX planned. Annual contracts with strategic customers offer volume stability; volume growth expected to track profitability growth. Impact of geopolitical and tariff disruptions acknowledged, with agile strategy adjustments in place. DCB volumes expected to recover

Future growth expectations in earnings/operating earnings/profits/EPS?

Aarti Industries projects a three-year EBITDA guidance target of Rs.1,800 crore, aiming for 20-25% CAGR growth. Growth levers include product portfolio expansion, cost optimization, and enhanced operating leverage from existing assets. New capacity expansions (e.g., MMA from 200 to 260 KTPA, Zone-IV, and MPP plants) are expected to contribute from H2 FY26 onwards and support margin improvement. Cost optimization initiatives worth Rs.150-200 crore are in advanced stages, with 65-70% expected to be implemented within the current year, leading to future profit accruals. Despite short-term

IN US

Sale is live|00:00:00left today

Aarti Industries LtdQ2 FY25Chemicals & Petrochemicals

Aarti Industries Ltd Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹457P/E: 41.0Market Cap: ₹16.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Growth levers are clear and being implemented to achieve Rs. 1,800 crore revenue target with 20-25% CAGR.
→Focus on expanding global markets, especially beyond the US for key products like MMA due to tariff uncertainties.
→Capacity expansions, such as scaling MMA capacity from 200 KTPA to 260 KTPA, are ongoing with minor additional CAPEX planned.
→Annual contracts with strategic customers offer volume stability; volume growth expected to track profitability growth.
→Impact of geopolitical and tariff disruptions acknowledged, with agile strategy adjustments in place.
→DCB volumes expected to recover in the second half as US customer inventory liquidation stabilizes.
→New product lines from Zone-IV and MPP plants commissioning from H2 FY26 onwards will contribute to future growth.
→Ongoing cost optimization and operational improvements aim to support margin and volume growth simultaneously.

Margin guidance

Category 3

→Aarti Industries projects a three-year EBITDA guidance target of Rs.1,800 crore, aiming for 20-25% CAGR growth.
→Growth levers include product portfolio expansion, cost optimization, and enhanced operating leverage from existing assets.
→New capacity expansions (e.g., MMA from 200 to 260 KTPA, Zone-IV, and MPP plants) are expected to contribute from H2 FY26 onwards and support margin improvement.
→Cost optimization initiatives worth Rs.150-200 crore are in advanced stages, with 65-70% expected to be implemented within the current year, leading to future profit accruals.
→Despite short-term disruptions (tariffs, geopolitical issues), management remains confident about demand and volume growth supporting profitability recovery.
→Strategic focus on high-value advanced chemistries and diversified end markets aims at achieving a 20%+ EBITDA margin profile over the long term.
→Annual earnings guidance is not provided due to market uncertainties, but the three-year outlook remains robust and achievable.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company has become more stringent in capital allocation over the past year.
→Current and upcoming capex projects like MMA expansions and Zone-IV are largely committed from earlier decisions, with a tapering overall capex trend.
→Capex guidance for FY26 is around Rs. 1,000 crore, down from approximately Rs. 1,300-1,400 crore the previous year.
→Future capex plans will be evaluated rigorously based on demand and return criteria.
→No explicit mention of fresh fundraising through debt or equity in the provided transcript.
→Focus appears to be on optimizing current assets, cost savings, and phased project commissioning rather than immediate capital raising.

Order book

→The document does not explicitly mention the current or expected order book or pending orders in precise numbers.
→However, it is mentioned that there are secured annual contracts with some major customers, especially in products like DCB.
→The company is confident of recovering volumes in the second half of the year once customer inventory corrections stabilize.
→Export volumes, particularly for MMA, are strong, with 20,000-22,000 tons exported in July including deferred shipments.
→Expansion projects such as Zone-IV and Multipurpose Plant (MPP) are underway with phased commissioning planned from H2 FY26, expected to add new products and improve margins.
→JV and strategic projects are progressing to expand market presence.
→Overall, the company is focused on expanding capacity, securing long-term partnerships, and diversifying customer and geographic reach, indicating a healthy order pipeline and market demand.

Capex plans

Yes

→Ongoing capacity enhancements include scaling up Nitrotoluene capacity from 30 to 45 KTPA and Ethylation from 10 to 30 KTPA, currently in ramp-up phase.
→MMA capacity scaled up from 200 KTPA to 260 KTPA, with potential for further expansion with limited capex.
→Zone-IV project commissioning is expected in a phased manner from H2 FY26, introducing newer high-margin products in advanced polymers, agrochemicals, and pharmaceuticals.
→Augene Chemical Pvt Ltd (JV with UPL) progressing well, commissioning expected in H1 CY26, with market development underway.
→Re Aarti Pvt Ltd project through Aarti Circularity Ltd has completed technology selection; capex finalization and preprocessing design in progress, targeting commercial operations early FY27.
→Capex for FY26 expected below Rs.1,000 crore, with a stringent capital allocation strategy focusing on demand-backed investments and high returns.
→Future expansions like multipurpose plants (MPP) and Zone-IV aim to enhance margin profiles and foray into sunrise sectors like defense and electronics with specific investments ongoing.

How does Aarti Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aarti Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aarti Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio